Document:

Research and Collaboration Agreement

 Exhibit 10.7 
 Research Collaboration 
 This Agreement is entered
into effective on this 20th day of January, 2010 (the
“Effective Date”) by and between MERCK SHARP & DOHME CORP (formerly Merck & Co., Inc.), having offices at One Merck Drive, Whitehouse Station, NJ 08889 (hereinafter referred to as, “Merck”), and BG
MEDICINE, INC., a private diagnostic development services company having offices at 610 Lincoln Street, Waltham, MA 02451 (“BGM”). Hereinafter, Merck and BGM are individually referred to as a “Party,” collectively as
the “Parties”. 
 WHEREAS BGM has developed expertise in in Vitro Diagnostics Device development, has recently completed
development of a certain biomarker-based diagnostic assay with application to congestive heart failure, and has an interest in the discovery and development of diagnostics in the area of cardiovascular disease; and 
 WHEREAS, Merck has interest in the development of therapeutics that inhibit the function of circulating [***] for the treatment of hypercholesterolemia and
coronary heart disease, and has developed a human [***] and reagents and completed fit for purpose assay validation on the MSD analyzer; and 
 WHEREAS, Merck has an interest in clinical qualification research (understanding the biology and pathophysiology related to [***]) and has access to internal cohorts of biological samples of interest; and 
 WHEREAS, BGM has access to additional biological cohorts of interest to Merck (e.g. [***]) applicable for the clinical qualification research and the
ability to collect additional biological samples via their partnership with [***]; and 
 WHEREAS, the Parties wish to collaborate to complete
clinical qualification research for circulating [***] and explore the opportunity for a broader [***] based on the outcome of such research, 
 NOW, THEREFORE, the Parties agree as follows: 
  

	1.	Definitions. 

 “Affiliate” of Merck shall mean any entity (i) in which fifty percent (50%) or more of the voting equity interests are now or hereafter owned or controlled, directly or indirectly, by Merck, (ii) which now or
hereafter owns or controls, directly or indirectly, fifty percent (50%) or more of the voting equity interests of Merck, or (iii) in which fifty percent (50%) or more of the voting equity interests are now or hereafter owned or
controlled, directly or indirectly, by an entity identified in the preceding clause (i) or (ii). 
 “Agreement”
shall mean this Agreement between Merck and BGM. 
 “BGM Information and Inventions” shall mean all Information,
protocols, formulas, data, Inventions, know-how and trade secrets, patentable or otherwise, resulting from the Research developed or invented (in the case of Inventions) solely by employees of BGM or other persons not employed by Merck acting on
behalf of BGM. 
 “Cause” is defined in Paragraph 14(b). 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s

 application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 1 

 “Confidential Information” is defined in Paragraph 6. 
 “Final Report” is defined in Paragraph 7. 
 “Information” shall mean any and all information and data, including without limitation all know-how, and all other scientific, pre-clinical, clinical, regulatory, manufacturing, marketing,
financial and commercial information or data, whether communicated in writing or orally or by any other method, which is provided by one Party to the other Party in connection with this Agreement. 
 “Invention” shall mean any process, method, composition of matter, article of manufacture, discovery or finding that is conceived
and/or reduced to practice as a result of the Research. 
 “In Vitro Diagnostic Device” or (“IVDD”)
is defined as reagents, instruments, and systems intended for use to measure [***] in serum or plasma for use in the diagnosis of disease or other conditions, including a determination of the state of health, in order to cure, mitigate, treat, or
prevent disease or its sequelae. 
 “Joint Information and Inventions” shall mean all Information, protocols,
formulas, data, Inventions, know-how and trade secrets, patentable or otherwise, resulting from the Research developed or invented (in the case of Inventions) jointly by employees of Merck and BGM or others acting on behalf of Merck and BGM, and all
Joint Materials. 
 “Joint Materials” shall mean research and diagnostic tools and reagents generated and/or developed
jointly by Merck and BGM during the Term. 
 “Merck Material” shall mean the Merck Samples and the Merck Reagent.

 “Merck Samples” shall mean clinical samples supplied by Merck for use in the Research under this Agreement.

 “Merck Reagents” shall mean Merck’s proprietary [***] reagents supplied by Merck for use in the Research under
this Agreement. 
 “Merck Information and Inventions” all Information, protocols, formulas, data, Inventions, know-how
and trade secrets, patentable or otherwise, resulting from the Research developed or invented (in the case of Inventions) solely by employees of Merck or other persons not employed by BGM acting on behalf of Merck, Merck Reagents, Merck Samples and
any other items supplied by Merck or its Affiliates to BGM hereunder or developed solely by Merck hereunder. 
 “Personal
Data” is defined in Paragraph 11. 
 “Research” shall mean the research described in the Work Plan, which is
being conducted for the purpose set forth in Paragraph 2. 
 “Term” is defined in Paragraph 4. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s

 application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 2 

 “Work Plan” shall mean the Work Plan attached as Exhibit A and Exhibit B.

  

	2.	Purpose. BGM and Merck agree to diligently perform the obligations described in Work Plan in for the purpose of developing targeted [***] (the
“Research”). 

  

	3.	Merck Material. Merck shall make available to BGM, for its use in the Research and at no cost to BGM, sufficient samples of the Merck Material to carry out the
Research. The Merck Material is not be used in humans. Except as provided herein, it is understood that the Merck Material is provided only in association with the performance of the Research and shall not be used for any other purpose, nor shall
the Merck Material or any derivatives, analogs, modifications or components thereof be transferred, delivered or disclosed to any third party without the advance written consent of Merck. 

  

	4.	Term. This Agreement shall be effective on the Effective Date. The term of this Agreement shall expire eighteen months (18) months following the Effective
Date, subject to early termination as provided in Paragraph 14 of this Agreement (the “Term”). 

  

	5.	Amount. In consideration of the Research, Merck shall pay BGM a total of [***] United States dollars ($[***]) payable as follows: 

  

	 	1)	[***] United States dollars ($[***]) within forty-five (45) days of execution of this Agreement and receipt of an invoice by Merck; and 

 

	 	2)	[***] United States dollars ($[***]) within forty-five (45) days of completion of Milestone B (as defined in the Work Plan) and Merck’s receipt of an invoice
from BGM. 

  

	6.	Confidentiality. BGM agrees to keep confidential and not to use, except for the purpose of conducting the Research, the Merck Information and Inventions. These
obligations of confidentiality and non-use shall continue during the Term of this Agreement and even after the Term expires. These obligations of confidentiality and non-use shall not apply to such Merck Information and Inventions which are
(i) in the public domain by use and/or publication before its receipt from Merck or development under the Research, or thereafter enters the public domain through no fault of BGM; (ii) already in BGM’s possession prior to receipt from
Merck or development under the Research, as evidenced by BGM’s written records; or (iii) properly obtained by BGM from a third party which has a valid right to disclose such information to the BGM and is not under a confidentiality
obligation to Merck. 

  

	7.	 Reports; Use of Information. BGM shall keep Merck informed of the progress of the Research by written reports on a bi-monthly (six
(6) times per year) basis and will provide a complete written report of all data generated and Research results to Merck at the end of the Term (the “Final Report”). Merck and its Affiliates shall have the unrestricted right to use
and disclose all information in the Research reports and to use and disclose any technical information developed pursuant to this Agreement, for any and all purposes Merck and its Affiliates deem necessary or advisable in the ordinary course of
business. At Merck’s request, BGM shall provide to Merck copies of all

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s

 application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 3 

	 	 
documentation and data relating to the Research or shall permit Merck to inspect and copy such documentation and data. 

  

	8.	Research Information and Inventions. 

 The entire right, title and interest in: 
  

	 	(a)	BGM Information and Inventions shall be owned solely by BGM; 

  

	 	(b)	Merck Information and Inventions shall be owned solely by Merck; and 

  

	 	(c)	Joint Information and Inventions shall be owned jointly by BGM and Merck. 

 BGM shall promptly disclose to Merck in writing the development, making, conception or reduction to practice of all Inventions. 
  

	9.	License Grant. 

  

	 	(A)	Merck hereby grants to BGM: 

 1)    A non-exclusive license to Merck Reagents for use in the research and development of an In Vitro Diagnostic Device for any and all purposes. In the event Merck intends to
grant a license to Merck Reagents for use in the research and development of an In Vitro Diagnostic Device to another licensee and under which the licensee would have commercial rights to the In Vitro Diagnostic Device, Merck will
notify BGM within thirty (30) days of granting such a license, in which case BGM may, at its sole discretion, cease all activities under this Agreement without any further obligations to Merck under this Agreement. At no point may Merck
disclose any BGM Information and Inventions to such licensee. 
 2)    An exclusive
license (but for Merck) to Merck’s rights in Joint Information and Inventions for the sole purpose of developing and commercializing an In Vitro Diagnostic Device, except to the extent such Joint Information and Invention contains Merck
Reagents or any prophylactic or therapeutic use of any component of the Merck Reagent, wherein such case the license granted herein to such Merck Reagents shall be exclusive of use in an In Vitro Diagnostic Device only and any prophylactic or
therapeutic use of any component of the Merck Reagent shall be non-exclusive, provided that: 
  

	 	(a)	Merck retains rights in Joint Information and Inventions for research, drug discovery and development purposes; 

  

	 	(b)	Such exclusive rights shall revert to non-exclusive rights if: 

  

	 	(i)	BGM fails to produce an IVDD substantially in accordance with the plan and timeline of Exhibit B; 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s

 application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 4 

	 	(ii)	BGM can not perform the appropriate analytical and clinical utility experiments to meet regulatory requirements for the IVDD in a given regulatory region for which the
[***] is being registered; 

  

	 	(iii)	BGM is likely to cause a delay in clinical study initiation or data delivery for diagnostic use or diagnostic approval because the IVDD or data is not ready; or

  

	 	(iv)	BGM can not make available or market, sell and distribute the IVDD in a major marketing territory. 

  

	 	(B)	BGM hereby grants to Merck: 

 1)    A non-exclusive license to BGM Information and Inventions for research, drug discovery and development purposes, provided that such purposes do not include commercial development
of an IVDD by Merck or a third party working on behalf of Merck. 
 2)    A non-exclusive
option to determine [***] under the control and ownership of BGM and report such results to Merck. BGM will perform [***] at no cost to Merck if BGM deems such study to be of regulatory importance or commercial interest to BGM. All other samples,
except the Merck Samples that are subject to Milestone B in Exhibit A, are subject to a reasonable and customary laboratory service fee for [***]. 
  

	10.	Publication. Notwithstanding Paragraph 6, Merck acknowledges BGM’s interest in publishing research results, and BGM acknowledges Merck’s interest in
protecting the Inventions arising from the Research and the confidentiality of the Merck Information and Inventions. BGM shall provide Merck for review any proposed manuscript, abstract, poster or oral presentation relating to the Research at least
forty-five (45) days prior to submission for publication or presentation. Within such forty-five (45) day period, Merck shall advise BGM of, and BGM shall take, appropriate action to protect Merck Information and Inventions, including
reasonable delay of the publication to permit patent filings or modification of the publication to delete Merck Information and Inventions. Until this publication process is completed or, if applicable, confidentiality is specifically waived under
Paragraph 6, Merck Information and Inventions and the results of the Research, shall be kept confidential and not disclosed by BGM. However, in no event shall the total period of delay permitted for the publication process set forth in this
Paragraph 10 exceed one hundred and twenty (120) days. 

  

	11.	 Compliance With Law. BGM shall conduct the Research in accordance with all applicable laws, rules and regulations, including, without
limitation, all current governmental regulatory requirements. In addition, BGM will comply with the Animal Welfare Act or any other applicable local, state, national and international laws or regulations relating to the care and use of laboratory
animals. Merck encourages BGM to use the highest standards, such as those set forth in the Guide for the Care and Use of Laboratory Animals (NRC, 1996), for the humane handling, care and treatment of such research animals. Any animals which receive
the Merck Material in the course of the

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s

 application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 5 

	 	 
investigation, or products derived from those animals, such as eggs or milk, will not be used for food purposes, nor will these animals be used for commercial breeding purposes. BGM will notify
Merck in writing of any deviations from applicable regulatory or legal requirements. BGM hereby certifies that it will not and has not employed or otherwise used in any capacity the services of any person debarred under Section 21 USC 335a in
performing any services hereunder. 

  

	12.	Use of Human Materials. Each of the Parties represents and warrants (i) that it has complied, or shall comply, with all applicable laws, guidelines and
regulations relating to the collection and/or use of the Samples and (ii) that it has obtained, or shall obtain, all necessary approvals consents, and/or authorization required by law for the collection, use and/or transfer of such Human
Material as contemplated by this Agreement. The Parties shall provide documentation of such approvals, consents and authorizations upon the other Party’s request. The Parties further represents and warrants that such Samples may be used as
contemplated in this Agreement without any obligations to the individuals or entities (“Providers”) who contributed the Samples, including, without limitation, any obligations of compensation to such Providers or any other third party for
the intellectual property associated with the Samples or the commercial use thereof for any purposes. 

 Notwithstanding anything to the contrary in Paragraph 6, BGM shall hold in confidence all data that identifies or could be used to identify Provider (“Personal Data”), except as required or permitted under this Agreement,
or to the extent necessary to be disclosed to regulatory agencies as part of the review process. In addition, notwithstanding anything to the contrary in Paragraph 6, BGM shall comply with all applicable laws and regulations, as amended from time to
time, with respect to the collection, use, storage, and disclosure of any Personal Data including without limitation, the U.S. Health Insurance Portability and Accountability Act (HIPAA) and the regulations promulgated thereunder. BGM agrees to
ensure that all appropriate technical and organization measures are taken to protect Personal Data against loss, misuse, and any unauthorized, accidental, or unlawful access, disclosure, alteration, or destruction, including without limitation,
implementation and enforcement of administrative, technical, and physical security policies and procedures applicable to Personal Data. 
  

	13.	Limitation of Liability. 

 Merck assumes no responsibility and shall have no liability for the nature, conduct or results of any research, testing or other work performed by or on behalf of BGM hereunder. BGM UNDERSTANDS THAT THE MERCK MATERIAL IS SUPPLIED “AS
IS” AND IS PROVIDED WITHOUT WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR ANY OTHER WARRANTY, EXPRESS OR IMPLIED. BGM ACKNOWLEDGES THAT THE MERCK MATERIAL IS EXPERIMENTAL IN NATURE AND MAY HAVE UNKNOWN HAZARDOUS
CHARACTERISTICS, THAT THEY ARE AWARE OF THE RISKS OF WORKING WITH EXPERIMENTAL MATERIALS, AND THAT THEY WILL STRICTLY ADHERE TO PROPER LABORATORY PROCEDURES FOR HANDLING CHEMICALS AND BIOLOGICAL SUBSTANCES WITH UNKNOWN

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s

 application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 6 

 
HAZARDS. THE MERCK MATERIAL WILL NOT BE USED IN HUMANS. MERCK WILL INFORM BGM OF ANY KNOWN TOXICITY OF THE MATERIAL. 
  

	14.	Termination. 

 (a)    Either Party may terminate this Agreement at any time, with or without cause, effective upon thirty (30) days’ written notice to the other Party. 
 (b)    In the event of a termination by Merck of this Agreement without Cause (as defined below), Merck shall reimburse
BGM for the pro-rata costs incurred in performance of the Research and for any non-cancelable commitments made, up to the date of termination; provided, however, that in no case will reimbursement under this Agreement exceed the amount specified in
Paragraph 5; provided, further, that BGM shall return to Merck any funds in excess of such pro-rata costs and non-cancelable commitments. If this Agreement is terminated by Merck for Cause, then in addition to any other remedies available to Merck,
no such reimbursement shall be paid by Merck to BGM and the grant of the non-exclusive license to the Merck Reagents shall be immediately terminated. For the purposes of the foregoing, “Cause” shall mean the failure by BGM to comply
with one or more of its material obligations under this Agreement. 
 (c)    Upon termination of this
Agreement, or at any other time that Merck may request, BGM agrees to return all Merck Information and Inventions, (and in the event of termination of the Agreement by Merck for Cause, the Merck Reagents) and all documents containing such Merck
Information generated by BGM in connection with the Research to Merck, except BGM may retain one copy in a secure location solely for record keeping purposes. 
  

	15.	Survival. The provisions of Paragraphs 3 (other than Merck’s obligations to supply the Merck Material), 6, 7, 8, 9, 10, 11,12, 13, 14, 15, 16, 17, 18, and
20 and all definitions relating to the foregoing, shall survive termination or expiration of this Agreement. 

  

	16.	Notices. Any notices required or provided by the terms of this Agreement shall be in writing, addressed in accordance with this Paragraph, and shall be delivered
personally or sent by certified or registered mail, return receipt requested, postage prepaid or by nationally-recognized express courier services providing evidence of delivery. The effective date of any notice shall be the date of first
receipt by the receiving Party. Notices shall be sent to the address/addressee given below or to such other address/addressee as the Party to whom notice is to be given may have provided to the other Party in writing in accordance with this
provision. 

  

	          If to Merck: 
	Vice President & Head 

 External Scientific
Affairs 
 Merck Sharp & Dohme Corp. 
 126 East Lincoln Ave. 
 RY70-200 
 Rahway, NJ 07065 
 ATTN: 64041 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s

 application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 7 

	          With a copy to: 
	Office of the Secretary 

 Merck Sharp & Dohme
Corp. 
 P.O. Box 100 
 One Merck Drive 
 Whitehouse Station, NJ 
 08889-0100 
  

	          Please send invoices to: 
	Merck Sharp & Dohme Corp. 

 PTP Shared Services

 PO Box 1700 
 Whitehouse Station, NJ 08889-1700 
 Phone: 908-236-3000 
 Fax: 908-823-3613 
 ATTN: 64041 
  

	          If to BGM: 
	President and CEO, BG Medicine 

 610 N Lincoln Street

 Waltham, MA 02451 
 Attn: President 
  

	17.	Entire Agreement. This Agreement, together with any Attachments attached hereto and specifically referenced herein, constitutes the entire agreement between the
Parties with respect to the Research and supersedes and replaces any and all previous arrangements and understandings, whether oral or written, between the Parties with respect to the Research. Any amendment or modification to this Agreement shall
be of no effect unless made in writing signed by an authorized representative of each Party. 

  

	18.	Publicity/Use of Names. No disclosure of the existence, or the terms, of this Agreement may be made by either Party, and no Party shall use the name, trademark,
trade name or logo of the other Party or its employees in any publicity, promotion, news release or disclosure relating to this Agreement or its subject matter, without the prior express written permission of the other Party, except as may be
required by law. 

  

	19.	Assignment. BGM may not assign its rights or obligations under this Agreement without the prior written consent of Merck, such consent not to be unreasonably
withheld. Merck may assign its rights and obligations hereunder to an Affiliate or in connection with the transfer or sale of all or substantially all of its assets related to the subject matter of this Agreement, or in the event of its merger or
consolidation or change in control or similar transaction, without the consent of BGM. Any such purported assignment not conforming with the previous sentence shall be void. 

  

	20.	Severability. The provisions of this Agreement are severable, and if any provisions hereof shall be determined to be invalid or unenforceable by a court of
competent jurisdiction, the remaining provisions shall continue in full force and effect. 

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s

 application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 8 

 IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their duly
authorized representatives, effective as of the date of the last signature set forth below. 
  

									
	MERCK SHARP & DOHME CORP.	 		 	BG MEDICINE, INC.
					
	BY:	 	/s/    Richard D. Tillyer	 		 	BY:	 	/s/    Pieter Muntendam
		 	Merck authorized representative	 		 		 	BG authorized representative
					
	TITLE:    	 	Richard D. Tillyer, Sr. VP	 		 	TITLE:    	 	Pieter Muntendam, President & CEO
					
	DATE:	 	January 28, 2010	 		 	DATE:	 	January 28, 2010

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s

 application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 9 

 EXHIBIT A 
 WORK PLAN 
 BGM Responsibilities: 
 1.    In-house [***] (Milestone A); to include [***]. [***], [***] on the BGM [***] developed under the [***] and
approved by the [***]. 
 2.    Conduct [***] on [***] provide by Merck and delivery data to Merck
(Milestone B); 
 3.    Conduct [***] cohort from BGM, (approx [***] samples) and delivery data to Merck
(Milestone C); 
 4.    During the Term of this agreement, BGM will in good faith, [***] results on [***]
BGM may choose to analyze based on BGM’s interest in advancing the diagnostic application of the assay; and 
 5.    Delivery of BGM Information and Inventions and Final Report to Merck (Numbers 4 and 5 are Milestone D). 
 Merck Responsibilities: 
 1.    Tech transfer of [***] to BGM, complete data analysis on [***] Samples and share
results of data analysis with BGM. Goal is to determine [***] to inform [***] or potential for [***]. 
 Timeline:  Milestones A, B
and C should be completed within [***] following transfer of Merck Reagents and Samples to BGM. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s

 application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 EXHIBIT B 
 IVDD Plan and Timeline 
 Upon completion of project milestones, BGM in conjunction with
Merck will determine the [***] for any of the following: treatment selection, assessment of cardiovascular risk and/or management of hypercholesterolemia. Work outlined in Exhibit A will provide the first dataset for assessment of clinical utility.

 Should clinical utility be established as a result of the work performed under this research collaboration, BGM will notify Merck of its
intentions with regard to development of an IVDD from the assay and in collaboration with Merck will work to: 
  

	 	a)	Define a [***] regulatory and launch strategy 

	 	b)	Identify [***] of the strategy and [***] from Merck or BGM for such studies 

	 	c)	Set an [***] to seek buy-in for the plan 

 At
such time, BGM will develop a detailed project plan and with milestones and timelines for [***] development to include plans for procurement and analysis of additional sample cohorts if deemed necessary for a successful [***]. For purposes of this
Agreement, a high level plan outlining the various components of an IVDD development plan and estimated timeframes is included herein. 
  

			
	 IVDD
Development
	  	[***]
	 [***]
	  	[***] months    
	 [***]
	  	[***] months    
	 [***]
	  	[***] months    
	 [***]
	  	[***] months    
	 [***]
	  	[***] months    
	 [***]
	  	[***] months    

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s

 application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended.Participation Agreement

 Exhibit 10.8 
 PARTICIPATION AGREEMENT 
 This Participation Agreement
(this “Agreement”) is entered into as of the 22nd day of December, 2006 (the “Effective Date”) by and between BG Medicine, Inc., a corporation having offices at 610 N. Lincoln Street, Waltham, Massachusetts 02451
(“BGM”) and Philips Medical Systems Nederland B.V. a company having offices at Veenpluis 4-6, 5684 PC Best, the Netherlands (“Philips” and “Participant”); each of Participant and BGM are sometimes referred to
individually as a “Party” and collectively as the “Parties”). 
 WHEREAS, BGM and Philips intend to
collectively design and conduct a number of activities (the “HRP Initiative”) in order to advance the understanding, recognition and management of High Risk Plaque for the benefit of all stakeholders in the healthcare system as described
in the form of Program Outline to be attached hereto as Exhibit A-1 (the “HRP Program, as further defined below”); and 
 WHEREAS, BGM will administer, coordinate and implement the HRP Program; and 
 WHEREAS, Participant desires to sponsor the HRP Initiative and to obtain access to the data generated in the performance of the HRP Initiative, and a non-exclusive license under certain intellectual property rights, as set forth herein.

 NOW, THEREFORE, in consideration of the foregoing, and other good and valuable consideration, the receipt and sufficiency of
which are hereby acknowledged, the Parties, intending to be legally bound, hereby agree as follows. 
 1. Definitions.
Capitalized terms used herein shall have the definition provided in the introductory paragraph or recitals above, or the definition provided below, as applicable. 
 “Affiliate” means any corporation, firm, partnership or other entity which directly or indirectly controls or is controlled by or is under common control with a Party. For purposes of
this definition, “control” means ownership, directly or through one or more Affiliates, of (a) fifty percent (50%) or more of the shares of stock entitled to vote for the election of directors, in the case of a corporation,
(b) fifty percent (50%) or more of the equity interests in the case of any other type of legal entity, status as a general partner in any partnership, or (c) any other arrangement whereby a Party controls or has the right to control
the Board of Directors or equivalent governing body of a corporation or other entity. 
 “Confidential
Information” means confidential scientific, business, or financial information provided by one Party or other sponsor of the HRP Initiative (a “disclosing Party”) to any other Party or other sponsor of the HRP Initiative (a
“receiving Party”) pursuant to this Agreement; provided, that, Confidential Information does not include: 
  

	(a)	information that is or becomes publicly known or that is or becomes available from public sources; 

  

	(b)	information that is already known by the receiving Party, or information that is independently created or compiled by the receiving Party without reference to or use of
the provided information; or 

  

	(c)	information that relates to potential hazards or cautionary warnings associated with the production, handling, or use of the subject matter of the HRP Program; or

  

	(d)	information that is provided to the receiving Party by a third party who is not bound by obligations of confidentiality to the disclosing Party.

 “Data” means all data first produced in the performance of the HRP Initiative as described in
the HRP Program. 
 “Participant Proprietary Product” means any drug compound or medical device controlled by
Participant. For purposes of this definition, “control” means the possession by Participant of (a) a 50% or more ownership interest in a drug compound or medical device or (b) a licensing interest that permits Participant to
exclusively develop, manufacture and sell such drug compound or medical device in some or all indications, uses and countries. 
 “Project Invention” shall have the definition provided in Section 5.2. 
 “Reports” shall have the definition provided in Section 4. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 “HRP Program” means a written plan describing the activities to be carried
out in support of the HRP Initiative, as such written plan may be amended, modified or updated. Each HRP Program shall include the resource requirements of, and budget applicable to, the conduct of each HRP Program. The initial HRP Program shall be
developed by the SPB and approved by the JSC within sixty (60) days of the Effective Date and attached hereto as Exhibit A-1 and each additional HRP Program shall be developed by the SPB and approved by the JSC prior to the initiation of
any Program Activities with respect to each such HRP Program and attached hereto as addendums to Exhibit A. 
 “Program Activity” means the activities to be conducted as part of the HRP Initiative as described in the applicable HRP Program. 
 “Scientific Program Board” or “SPB” means the scientific advisory board comprised of academic experts in applicable fields, representatives of BGM, Participant, and other
sponsors of the HRP Initiative that are approved by the JSC, as further described in Section 3.2. 
 “Joint
Steering Committee” or the “JSC” means the joint steering committee comprised of those representatives of BGM, Participant, and other sponsors of the HRP Initiative, as further described in Section 3.1. 
 “Third Party Contractor” means any third party contract research organization, research laboratory or similar entity
engaged by Participant to perform development services with respect to any Participant Proprietary Product. 
 2. HRP Initiative.

 2.1 Performance of HRP Initiative. BGM shall coordinate, administer and execute the HRP Initiative as provided
in the HRP Program. The HRP Initiative shall be implemented through the conduct by BGM of Program Activities, each of which will be described in the HRP Program and/or in amendments thereto. 
 2.2 HRP Program; Amendments. Within sixty (60) days of the Effective Date the initial HRP Program shall be prepared by the
SPB, approved by the JSC and attached hereto as Exhibit A-1. Any changes to the HRP Program shall be prepared by the SPB and approved by the JSC in accordance with Section 3.1 below. 
 2.3 Additional Participants. Excluding BGM, the HRP Initiative shall have no less than two (2) sponsors (including
Participant). BGM will actively recruit additional participants (“Subsequent Participants”) until a total of five (5) Participants have executed participation agreements. To join the HRP Initiative, Subsequent Participants shall
execute participation agreements including substantially the same terms set forth in this Agreement. Subsequent Participants must execute participation agreements joining the HRP Initiative prior to 12/31/2007; Thereafter, Subsequent Participants
shall only be permitted to join the HRP Initiative with the consent of at least two-thirds of the JSC. Any terms of a Subsequent Participant’s agreement materially different from this Agreement shall be approved in writing by the JSC, in
addition to any approval process by which BGM is obligated, such approval not to be unreasonably withheld. 
 2.4 Open
Technology. In order to promote widespread availability and adoption of imaging technology inventions arising from the HRP Initiative that are specific to imaging technology equipment, and their applications to various types of imaging
equipment, these imaging technology equipment inventions and applications resulting from Philips’ use of the Project Inventions shall be made available, under customary multi-vendor terms and polices to GE, Siemens and any other
established manufacturer of proprietary imaging equipment who possesses the appropriate level of know-how and experience to implement new technology arising from the HRP Initiative. 
 3. Governance 
 3.1. Joint Steering Committee. 
 (a) Formation;
Responsibilities. As soon as practicable after the Effective Date, the Joint Steering Committee shall be formed to (i) oversee the overall conduct and progress of the HRP Initiative; (ii) establish such additional committees as may be
necessary to achieve the objectives of the HRP Initiative and, to the extent so established, approve the governing procedures applicable thereto; (iii) finalize and approve each Program Activity (including all budgets and work plans included
therein) and/or

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s
application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 2 

 
each amendment to any HRP Program proposed by the SPB; (iv) make all decisions with respect to the initiation and performance of any Program Activity and the application of funds to such
Program Activity; (v) approve all press releases related to the HRP Initiative; (vi) review and approve all patent filings to be made covering any Project Inventions; (vii) provide a forum for the resolution of disputes among the
Parties with respect to the HRP Initiative; (viii) negotiate, and if desirable, grant commercialization rights to the Data and Project Inventions; (ix) if necessary, dissolve the SPB; and (x) approve, and if necessary, replace or
discharge the Co-Chairs of the SPB. 
 (b) Designation of Representatives. BGM and each Participant shall have the right
to designate one (1) member to serve on the JSC. Participant shall provide written notice to BGM of the name of such member promptly after the Effective Date. Unless otherwise agreed by the Parties, (i) the Co-chairs of the SPB shall be
non-voting members of the JSC; (ii) the representatives of BGM and Philips on the JSC shall be the Co-Chairs of the JSC and (iii) the representative of BGM on the JSC shall serve as Secretary to the JSC. Each Party shall have the right at
any time to substitute individuals, on a permanent or temporary basis, for any of its previously designated representatives to the JSC by giving written notice to the other Party. 
 (c) Meetings. The JSC shall establish a schedule of times for regular meetings, taking into account, without limitation, the planning
needs of the HRP Initiative and the responsibilities of the JSC. The Secretary shall have the responsibility for preparing and circulating to each JSC member an agenda for each JSC meeting not later than one (1) week prior to such meeting. The
JSC shall meet not less than once per calendar quarter or at such other intervals as it deems appropriate. The Secretary shall give all members of the JSC proper and timely notice of any meeting to be held. Meetings of the JSC may be held in person
or by teleconference or videoconference. Upon prior request by any member of the JSC, any JSC meeting may be conducted excluding the Co-chairs of the SPB. 
 (d) Quorum. At each JSC meeting, (i) the presence of at least a majority of the JSC members shall constitute a quorum and (ii) each member who is present shall have one vote on all
matters before the JSC at such meeting. All decisions of the JSC shall be made by vote or written consent of the majority of all members. In the event that the JSC is unable to resolve any matter before it for consideration, such matter shall be
resolved in accordance with Section 3.1(f). 
 (e) Minutes; Updates. The JSC shall keep minutes of its meetings that
record all decisions and all actions recommended or taken in reasonable detail. Drafts of the minutes of each meeting, as well as an update on the status of all Program Activities, shall be prepared and circulated to the members of the JSC by the
Secretary within a reasonable time, not to exceed ten (10) business days, after the meeting. Each member of the JSC shall have the opportunity to provide comments on the draft minutes. Draft minutes shall be approved or disapproved
(and, in case of the latter, revised) as soon as practicable. Upon approval, final minutes of each meeting shall be circulated to the members of the JSC by the Secretary. 
 (f) Dispute Resolution. The JSC members shall use reasonable efforts to reach agreement on any and all matters presented to it. In
the event that, despite such reasonable efforts, the agreement on a particular matter cannot be reached by the JSC in accordance with Section 3.1(d) within ten (10) days after the JSC first meets to consider such matter (each such matter,
a “Disputed Matter”), then the JSC shall abandon consideration of the Disputed Matter and the subject matter of the Disputed Matter shall not be implemented. 
 3.2 Scientific Program Board. 
 (a) Formation; Responsibilities.
As soon as practicable after the Effective Date, the Scientific Program Board shall be formed to (i) provide advice on the direction and performance of the Program Activities that make up the HRP Initiative; (ii) propose and design Program
Activities for submission to and the approval of the JSC; (iii) propose such additional scientific subcommittees as may be necessary to achieve the objectives of any Program Activity for submission to and the approval of the JSC;
(iv) identify any public disclosure needs related to the HRP Initiative and develop scientific disclosure and publication materials for approval by the JSC; and (v) review and present to the JSC all Project Inventions. The SPB shall use

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 3 

 
reasonable efforts to reach agreement on any and all matters; provided, that, in the event that the SPB is unable to resolve any matter before it, such matter shall be referred to the JSC for
resolution. BGM shall give good faith consideration to the advice of the SPB with respect to the conduct of all Program Activities; provided, that BGM shall at all times adhere to the requirements of the HRP Program in the performance of the HRP
Initiative. 
 (b) Designation of Representatives. The JSC shall appoint the Co-Chairs and Secretary of the SPB, which
shall consist of scientific and academic leaders in the field of High Risk Plaque, scientists from Participant companies and/or individuals with expertise in other selected fields indirectly related to the High Risk Plaque Field such as patient
advocacy, medical specialty, payors or the federal government. Additional members of the SPB may be nominated by the SPB or by members of the JSC. The SPB shall approve new members or remove its members by a majority vote. In addition, after
approval by the SPB, new members of the SPB employed by for-profit corporations which are not sponsors of the HRP Initiative must be approved by the JSC. The JSC shall decide the maximum number of SPB members. The JSC may remove the Co-Chairs of the
SPB or dissolve the entire SPB at any time by majority vote with or without cause. 
 (c) Meetings. The SPB shall
establish a schedule of times for regular meetings, taking into account, without limitation, the planning needs of the HRP Initiative and the responsibilities of the SPB. The Secretary shall have the responsibility for preparing and circulating to
each SPB member an agenda for each SPB meeting not later than one (1) week prior to such meeting. The SPB shall meet not less than once per calendar quarter or at such other intervals as it deems appropriate. The SPB shall give all members of
the SPB proper and timely notice of any meeting to be held. Meetings of the SPB may be held in person or by teleconference or videoconference. 
 (d) Quorum. At each SPB meeting, (i) the presence of a majority of the SPB members shall constitute a quorum and (ii) each member who is present shall have one vote on all matters before
the SPB at such meeting. All decisions of the SPB shall be made by vote or written consent by the majority of all members. 
 (e) Minutes; Updates. The SPB shall keep minutes of its meetings that record all decisions and all actions recommended or taken in reasonable detail. Drafts of the minutes of each meeting, as well as an update on the status of all
Program Activities, shall be prepared and circulated to the members of the SPB and JSC by the Secretary within a reasonable time, not to exceed ten (10) business days, after the meeting. Each member of the SPB shall have the opportunity to
provide comments on the draft minutes. Draft minutes shall be approved or disapproved (and, in the case of the latter, revised) as soon as practicable. Upon approval, final minutes of each meeting shall be circulated to the members of the SPB by the
Secretary. 
 3.3 Initiative Manager. 
 (a) Designation. As soon as practicable after the Effective Date, BGM shall recruit and supervise a person who shall oversee the day-to-day conduct of the Program Activities (the
“Initiative Manager”). If requested by the SPB or JSC Co-chairs, the Initiative Manager may attend all meetings of the JSC and the SPB, as the case may be, as a non-voting participant. 
 (b) Responsibilities. The Initiative Manager shall be responsible for (i) planning, coordinating and managing the conduct
of the Program Activities; (ii) performing such tasks in support of the HRP Initiative as may be requested by the JSC. 
 4. Reports; Access to Data and Material; Confidentiality; Publication. 
 4.1 Reports;
Data. BGM shall provide the SPB with copies of all written reports (collectively, the “Reports”) that are prepared by it in connection with the conduct of any Program Activity within four (4) months following the completion of a
Program Activity or termination of the HRP Initiative. BGM shall also provide each Participant with copies of electronic files containing the Data as soon as practicable following analysis and reporting of a Program Activity. 
 4.2 Material. When possible, studies will be designed to provide extra materials for distribution to Participant and, if
requested by such party, the other sponsors. BGM shall provide Participant with aliquots of such materials collected and/or created during the HRP Initiative (“HRP Materials”). Participant may use the HRP Materials for research, drug
discovery and development purposes without further obligation to BGM or any other sponsor of the HRP Initiative. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 4 

 4.3 Confidentiality. Participant, BGM and the other sponsors shall not disclose
any Confidential Information received in connection with this Agreement, or the contents of any Reports (including without limitation, any Data) to any third party except for its Affiliates and its collaborators or advisors that are bound by
terms of confidentiality no less strict than those set forth herein, during the term of this Agreement and for a period of ten (10) years after the date of expiration or termination of this Agreement without the prior written consent of,
during the term of this Agreement, the JSC, and after the term of this Agreement, a majority of BGM, Participant and the other sponsors of the HRP Initiative. 
 This Agreement shall not restrict Participant, BGM or any other sponsor from complying with a lawfully issued governmental order or legal requirement, including the obligation to report adverse drug
experiences to competent regulatory authorities, to produce or disclose Confidential Information; provided, however, that Participant, BGM or any other sponsor, as applicable, shall promptly notify the party having disclosed Confidential Information
to enable such party to oppose the order or obtain a protective order and Participant, BGM or any other sponsor, as applicable, shall cooperate fully with the disclosing party in any such proceeding. 
 4.4 Publication. All publications or public presentations of the Data shall be prepared or approved by the SPB, subjected to
peer review in accord with prevailing scientific custom. The SPB shall provide the JSC with copies of any such publication or public presentation thirty (30) days prior to publication or public release. 
 5. IP Ownership; License Grants. 
 5.1 Ownership; Patent Filings. Subject to the rights granted to Participant and the other sponsors hereunder, all Project Inventions and Data shall be owned by BGM. Philips, as an agent for
BGM may at its own discretion be responsible for the preparation, filing, prosecution and maintenance of patents and patent applications covering Project Inventions. If Philips elects not to carry out such responsibility itself, BGM shall take
on the responsibility and Philips shall assist BGM in identifying a suitable intellectual property agent after which BGM will engage the agent. The charges of such agent shall be to the HRP Initiative. BGM shall (a) provide the JSC with copies
of all patent applications to be filed hereunder for Project Inventions in sufficient time to allow for review and comment by the JSC; (b) consult with the JSC regarding the filing and contents of any such application; and (c) take into
consideration in good faith the advice and suggestions of the JSC in connection with such filing. Following expiration of the term of this Agreement what is stated regarding the JSC in this Section 5.1 shall instead apply to Participant and
other sponsors of the HRP Initiative. In the event Participant terminates this Agreement prior to its expiration, what is stated regarding the JSC in this Section 5.1 shall for the purpose of this Section 5.1 include Participant as well.

 5.2 License Grant. BGM hereby grants to Participant a non-exclusive, perpetual, royalty-free, worldwide license
under all intellectual property rights that claim any Data and all inventions or discoveries made by BGM, whether alone or jointly with any third party (a) in the performance of HRP Initiative in accordance with the HRP Program or (b) on
and after the termination or expiration of this Agreement as a direct result of BGM’s use of the Data (collectively, “Project Inventions”), for use by Participant and its Affiliates for any and all purposes in their regular course of
business; provided that neither Participant, BGM or any other sponsor may sell or, except as provided in Section 5.3, sublicense the Data and Project Inventions. 
 The JSC may negotiate and, if desirable, direct BGM to, and BGM shall, as directed by the JSC, grant licenses to sell or sublicense the Data and Project Inventions. All proceeds of any such license shall
be used in furtherance of the HRP Initiative or, after the term of this Agreement, be distributed evenly between BGM, Participant and the other sponsors. BGM shall not grant any licenses or other intellectual property rights in or to the Project
Inventions and/or Data except as explicitly set forth in this Section 5.2. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 5 

 5.3 Use of Data. For avoidance of doubt, Participant and its Affiliates shall be
permitted to further analyze the Data, to combine the Data with its own data, and to use the Data for its internal purposes; provided, that, Participant and its Affiliates shall not publish any Data. Participant and its Affiliates may use the Data
in, and in support of, patent applications being submitted by or on behalf of Participant or its Affiliates. Participant shall have the right to sublicense to its Affiliates and Third Party Contractors the rights and licenses granted to it under
this Section 5.3 solely for the purpose of having any such Affiliate and/or Third Party Contractor perform services with respect to one or more Participant Proprietary Products; provided, that, it shall be a condition of any such sublicense
that such Affiliate and Third Party Contractor agrees to be bound by all of the applicable terms and conditions of this Agreement (including without limitation Section 4). If Participant grants any such sublicense to its Affiliates and/or Third
Party Contractors, Participant shall be deemed to have guaranteed that such Affiliate or Third Party Contractor will fulfill all of Participant’s obligations under this Agreement. No other rights or licenses are granted hereunder, by
implication or otherwise. Participant shall own all results, data and intellectual property developed or discovered through its use of the Data and Project Inventions without further obligation to BGM or the other sponsors of the HRP Initiative.

 6. Participation Payment. 
 6.1 Payment. Participant shall contribute a total of five million dollars (US$5,000,000), of which [***] dollars (US$[***]) shall be paid in cash, and the remainder will be contributed in
in-kind contributions by Participant to the HRP Program in the period 2006-2009. Participant shall pay BGM [***] dollars (US$[***]) in [***] (such amount, the “First Participation Payment”). Participant shall pay BGM [***] dollars
(US$[***]) in [***] (such amount, the “Final Participation Payment”) (the First Participation Payment and Final Participation Payment together the “Participation Payments”). In-kind contributions may, amongst others, be provided
in the form of loans of necessary imaging equipment for the HRP program activities, internal and external time and materials expenses incurred by Philips for providing technical support to the HRP program, adaptations and customizations of imaging
equipment and development and validation of image processing methods for plaque recognition and characterization. Philips in-kind contributions will be valued at reasonable and customary industry rates and equipment cost will be valued at average US
institutional equipment lease price. Philips will provide budget estimates for in-kind contributions for Program Activities upon request by the Alliance Manager. In-kind contributions for Program Activities will be detailed in the HRP Program budget
that is subject to JSC approval. Cash payments shall be made in accordance with wire transfer instructions to be provided by BGM. All payments made pursuant to this Section 6.1 shall be maintained by BGM in a dedicated account, which shall be
kept separate from, and not commingled with, any other funds. 
 6.2 Use of Funds. The Participation Payments shall
be used solely to perform the HRP Initiative. In the event that the Participation Payments, when aggregated with payments received from other sponsors, are insufficient to fund the HRP Initiative as set forth in the budget included as part of a HRP
Program (including as the same may be amended in accordance with this Agreement), then the JSC shall promptly meet to devise alternative plans, such as scaling back the HRP Initiative and/or identifying one or more alternative sources of funds;
provided, that, if Participant does not consent to an alternative plan or the obtaining of such alternative funds, then this Agreement shall be subject to termination by Participant on thirty (30) days notice to BGM from the date the proposal
concerned was being presented to Participant and the Participation Payments made by such Participant shall be refunded to Participant to the extent and as provided in Section 7. 
 7. Term; Termination. 
 7.1 Term. This Agreement
shall commence on the Effective Date and expire on the first to occur of: (i) the completion of the HRP Initiative and (ii) the fifth anniversary of the Effective Date. 
 7.2 Termination. This Agreement is subject to early termination by Participant (i) as provided in Section 6.2; or
(ii) at its discretion at any time following twelve (12) months of the Effective Date by giving thirty (30) days written notice. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 6 

 The JSC may terminate this Agreement and the HRP Initiative by majority vote for any or no reason.
Termination by the JSC will become effective immediately after approval by the committee. 
 7.3 Effect of Termination;
Survival. Upon any termination of this Agreement, any portion of the Participation Payments made by a Participant which has not been spent in performance of the HRP Initiative, after deducting amounts committed for non-cancelable commitments,
shall be promptly refunded by BGM to Participant. The rights and obligations of the Parties set forth in Sections 1, 4, 5, 7 and 8 shall survive the termination or expiration of this Agreement; provided, however, that notwithstanding
Section 5.2, in case Participant terminates the Agreement in accordance with Section 7.2 (ii) the survival under Section 5 will be regarding such rights and obligations as they were on the effective date of such termination.

 8. Miscellaneous. 
 8.1. NO WARRANTIES. EXCEPT AS SPECIFICALLY STATED HEREIN, THE PARTIES MAKE NO EXPRESS OR IMPLIED WARRANTY AS TO ANY MATTER WHATSOEVER, INCLUDING THE CONDITIONS OF THE RESEARCH OR ANY
INVENTION, MATERIAL, OR DATA, WHETHER TANGIBLE OR INTANGIBLE, MADE OR DEVELOPED UNDER OR OUTSIDE THE SCOPE OF THIS AGREEMENT OR THE OWNERSHIP, MERCHANTABILITY, OR FITNESS FOR A PARTICULAR PURPOSE OF ANY INVENTION, DATA OR MATERIAL, OR THAT A
TECHNOLOGY UTILIZED BY A PARTY IN THE PERFORMANCE OF THE HRP PROGRAM DOES NOT INFRINGE ANY THIRD-PARTY PATENT RIGHTS. 
 8.2. Indemnification and Liability. Participant agrees to hold BGM (“Indemnitee”), and each of its respective officers, directors, employees and agents, harmless and to indemnify Indemnitee for all liabilities,
demands, damages, expenses and losses (“Losses”) arising out of the use by Participant of the Data and/or the Project Inventions, for any purpose; provided, however, that such indemnification shall not be provided to Indemnitee for a
Losses to the extent such Losses arises out of: (i) a breach of this Agreement by Indemnitee, (ii) a deviation from the HRP Program by Indemnitee, or (iii) the negligence or willful misconduct of Indemnitee. 
 At its option, Participant may assume the defence of any claim by a third party for which indemnity is sought by Indmenitee hereunder, by giving written
notice to the Indemnified Party. 
 Indemnitee shall not admit any liability with respect to, or settle, compromise or discharge, any claim by a
third party for which indemnity is sought by Indmenitee hereunder without the prior written consent of Participant. 
 8.3. Governing Law. The construction, validity, performance and effect of this Agreement will be governed by the laws of the State of New York without regard to provisions relating to conflicts of laws. Any dispute arising out
of or relating to this Agreement shall be addressed amicably in accordance with Section 3.1(f). In the event a resolution to the dispute cannot be obtained, the dispute shall be resolved through arbitration before three
(3) arbitrators. Such arbitration shall take place in New York City, NY and shall proceed in accordance with the commercial arbitration rules of the American Arbitration Association (“AAA”) and the laws of the state of New York
without regard to the provisions thereof concerning conflict of laws. 
 8.4. Waivers. None of the provisions of
this Agreement will be considered waived by any Party unless a waiver is given in writing to the other Party. The failure of a Party to insist upon strict performance of any of the terms and conditions hereof, or failure or delay to exercise any
rights provided herein or by law, will not be deemed a waiver of any rights of any Party. 
 8.5. Amendments. This
Agreement shall only be amended by a written amendment signed by BGM and Participant. 
 8.6. Assignment. Neither
this Agreement nor any rights or obligations of any Party hereunder will be assigned or otherwise transferred by either Party without the prior written consent of the other Party. 
 8.7. Notices. All notices pertaining to or required by this Agreement will be in writing, signed by an authorized representative
of the

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 7 

 
notifying Party, and delivered by first class, registered, or certified mail, or by an express/overnight commercial delivery service, prepaid and properly addressed to the other party at the
address set forth above, or to any other address designated in writing by the other Party. Notices to BGM shall be directed to “President;” notices to Philips shall be delivered to Vice President Strategy; Philips Medical Systems. Notices
will be considered timely if received on or before the established deadline date or sent on or before the deadline date as verifiable by U.S. Postal Service postmark or dated receipt from a commercial carrier. Any Party may change its address by
notice given to the other Party in the manner set forth above. 
 8.8. Use of Name; Press Releases. Participant
shall not issue any press releases, or make other public statements, that include reference or rely upon the Data or the HRP Program without the prior written consent of the JSC. The JSC shall approve and issue all press releases related to the HRP
Initiative. Notwithstanding the foregoing, BGM, Philips and Participant shall each have the right to publicize Participant’s support of the HRP Initiative. 
 IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the Effective Date. 
 BG
Medicine, Inc. 
  

			
	 By:
	 	 /s/ Pieter Muntendam

	Name:	 	Pieter Muntendam
	Title:	 	President

  

									
	Philips Medical Systems Nederland, B.V.	 		 	Philips Medical Systems Nederland, B.V.
					
	 By:
	 	 /s/ R.M.M. Fonville
	 		 	By:	 	 /s/ W. Vuisting

	 Name:
	 	R.M.M. Fonville	 		 	Name:	 	W. Vuisting
	 Title:
	 	SVP, Philips Medical Systems	 		 	Title:	 	SVP, Philips Medical Systems
	 Date:
	 	29-01-2007	 		 	 Date:
	 	30-01-2007

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 8 

 Exhibit A-1 
 HRP Program – Version 0.4 
 Background 
 The HRP Program is a pre-competitive multi-year program that encompasses original research and other activities to support the development of a novel
clinical paradigm for high-risk plaque. 
 The program is governed by a Joint Steering Committee (JSC) and Scientific Program Board as outlined
in the Participation Agreement. 
 The JSC is responsible for the development of the initial HRP Program and its subsequent expansions and
modifications. 
 The following studies are in various stages of design and planning as authorized by the JSC. None of the studies and the
corresponding study budgets have been approved by JSC and all activities listed here are subject to SPB review and JSC review and approval. 
 Current Program Outline 
  

			
	Title:	  	Biomarker Discovery of High-Risk Patient
	Partner:	  	Duke University Medical School, NC, USA
	Objective:	  	Identification of biomarkers that correspond to an increased risk for coronary events
	Design:	  	Case-control study using specimen from CATHGEN biobank
	Start:	  	Jan 2007
		
	Title:	  	Systems Biology of Human Carotid Plaque
	Partner:	  	CARIM – Univ. of Maastricht, The Netherlands
	Objective:	  	Identification of plaque biomarkers of human plaque
	Design:	  	Comparative systems analysis involving two high-risk plaque types
	Start:	  	Oct 2006 (method development); May 2007 (full study)
		
	Title:	  	BioImage Study
	Partner:	  	Humana, Univ. of Miami
	Objective:	  	Identification of plasma and imaging biomarkers with superior characteristics than Framingham Risk Score
	Design:	  	Prospective outcomes study in at-risk volunteers recruited from health insurance plan with monitoring of three-year event-rates
	Start:	  	May 2007
		
	Title:	  	BioIvus Study
	Partner:	  	EMC, Rotterdam, The Netherlands
	Objective:	  	Comparison of non-invasive BioImage imaging methods with IVUS (including palpograpgy and virtual histology)
	Design:	  	Prospective non-comparative study in patients involving
	Start:	  	March 2007

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 A-1 

			
	Title:	  	Translational Study on Gottingen Mini-Pig
	Partner:	  	Aarhus University, Denmark
	Objective:	  	Translational study on coronary plaque of 3 year-old mini-pig fed a high-cholesterol diet to determine suitability for
human imaging method development or pre-clinical testing
of interventions
	Design:	  	Post-mortem study on existing herd of mini-pigs that were fed a high-cholesterol diet for three years.
	Start:	  	April 2007
		
	Title:	  	Regulatory Framework
	Partner:	  	Covington & Burling, DC, USA
	Objective:	  	Define a regulatory framework for diagnostic and therapeutic products for high-risk plaque
	Design:	  	n.a.
	Start:	  	October 2006

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 A-2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00170-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00170-of-00352.parquet"}]]